drugset / Trial / NCT07171034
A Phase I Study of KLA318-2 Nanocrystal Injection
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Celecoxib | Other / unclassified | 200 mg | Oral |
| Comparator | Celecoxib | Other / unclassified | 400 mg | Oral |
| Subject | KLA318-2 | Unknown | 60 mg | Intravenous |
| Subject | KLA318-2 | Unknown | 120 mg | Intravenous |
| Subject | KLA318-2 | Unknown | 180 mg | Intravenous |
| Subject | KLA318-2 | Unknown | 240 mg | Intravenous |
Indications
No indication recorded.